MyJournals Home  

RSS FeedsA serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice (BMC Cancer)

 
 

17 september 2014 07:50:07

 
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice (BMC Cancer)
 


Background: Malignant mesothelioma (MM) carries a poor prognosis and response rates to palliative chemotherapy remain low. Identifying patients with MM that are unlikely to respond to chemotherapy could prevent futile treatments and improve patient quality of life. Studies have suggested that soluble mesothelin is a potential biomarker for early diagnosis and prognosis of MM. We set out to explore the utility of serum mesothelin in routine clinical practice. Methods: We conducted a prospective exploratory study of serum mesothelin levels in 53 consecutive patients with MM at our institution between April 2009 and February 2011. Survival was assessed and analysed by mesothelin level as both continuous and categorical variables using Cox regression models. Differences in response rate between treatment groups were assessed by the Kruskal-Wallis Test. Results: All 53 patients, who had been given study information agreed to participate. The patients` median age was 69 (range 24-90). Median mesothelin level was 2.7nM and this value was used to dichotomize categories: 2.7nM (high). The progression free survival (PFS) for low vs high mesothelin was 8.0 vs 5.1 months (HR 1.8, p-0.058). When mesothelin was accessed as a continuous variable for PFS the HR was 1.03 (95% CI: 1.01 - 1.06; p = 0.013). The overall survival (OS) for low vs high mesothelin was 17.2 vs 11.3 months (HR 1.9, p = 0.088). When mesothelin was assessed as a continuous variable for OS the HR was 1.02 (95% CI: 0.99 - 1.04; p = 0.073). Thirty patients received chemotherapy of which 18 had a pre-chemotherapy serum mesothelin level. In these 18 patients, the pre-chemotherapy mesothelin level did not correlate with response. Conclusions: A single random sample provides information about patient prognosis but does not predict treatment response. We suggest further prospective validation of mesothelin testing as a prognostic biomarker.


 
101 viewsCategory: Oncology
 
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination (Breast Cancer Research)
Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-beta-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system (Molecular Cancer)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:

Oncology


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten